Predictors of Survival and Modes of Failure After Mitroflow Aortic Valve Replacement in 1,003 Adults

Midterm follow-up shows acceptable hemodynamic performance of the Mitroflow biologic aortic valve prosthesis in selected patients 60 years old and older. Ongoing follow-up will be necessary to understand long-term performance and outcomes.